GIA
GSK icon

Gladstone Institutional Advisory’s GSK GSK Stock Holding History

Gladstone Institutional Advisory’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Sell
8,719
-518
-6% -$27.4K 0.01% 617
2026
Q1 		$510K Buy
9,237
+280
+3% +$15.2K 0.02% 535
2025
Q4 		$439K Sell
8,957
-1,126
-11% -$52.5K 0.02% 526
2025
Q3 		$435K Sell
10,083
-1,431
-12% -$55.9K 0.02% 555
2025
Q2 		$442K Buy
11,514
+22
+0.2% +$841 0.02% 528
2025
Q1 		$445K Sell
11,492
-729
-6% -$26.7K 0.02% 493
2024
Q4 		$413K Buy
12,221
+407
+3% +$14.7K 0.02% 513
2024
Q3 		$483K Buy
11,814
+1,410
+14% +$57.7K 0.02% 458
2024
Q2 		$401K Sell
10,404
-900
-8% -$37.9K 0.02% 473
2024
Q1 		$485K Sell
11,304
-56
-0.5% -$2.31K 0.03% 421
2023
Q4 		$421K Sell
11,360
-333
-3% -$12K 0.02% 447
2023
Q3 		$424K Sell
11,693
-495
-4% -$17.6K 0.03% 415
2023
Q2 		$434K Sell
12,188
-371
-3% -$13.3K 0.03% 432
2023
Q1 		$447K Buy
12,559
+660
+6% +$23.1K 0.03% 432
2022
Q4 		$418K Buy
11,899
+4,444
+60% +$148K 0.03% 434
2022
Q3 		$219K Sell
7,455
-481
-6% -$18.2K 0.02% 565
2022
Q2 		$432K Sell
7,936
-2,248
-22% -$124K 0.03% 440
2022
Q1 		$555K Sell
10,184
-7,133
-41% -$387K 0.04% 409
2021
Q4 		$955K Buy
17,317
+11,122
+180% +$579K 0.07% 271
2021
Q3 		$296K Buy
+6,195
New +$311K 0.03% 431
2020
Q4 		– Sell
-6,526
Closed -$307K – 310
2020
Q3 		$307K Buy
+6,526
New +$327K 0.07% 205
2020
Q1 		– Sell
-4,442
Closed -$261K – 289
2019
Q4 		$261K Sell
4,442
-1,531
-26% -$85.2K 0.06% 212
2019
Q3 		$319K Sell
5,973
-565
-9% -$29.1K 0.08% 194
2019
Q2 		$327K Buy
+6,538
New +$328K 0.1% 188

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Gladstone Institutional Advisory's GSK Position: Q2 2026 in Review

Gladstone Institutional Advisory reduced its GSK (GSK) stake by 5.6% in Q2 2026, selling an estimated $27.4K and leaving 8,719 shares worth $457K. The position accounts for 0.01% of the portfolio, ranked #617.

Gladstone Institutional Advisory first reported a position in GSK in Q2 2019 and has held it in 24 quarters since. The position peaked at $955K in Q4 2021. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Gladstone Institutional Advisory held 8,719 shares of GSK worth $457K as of Q2 2026.
  • Gladstone Institutional Advisory sold 518 GSK shares in Q2 2026, an estimated $27.4K.
  • GSK made up 0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #617 holding.
  • Gladstone Institutional Advisory first reported a position in GSK in Q2 2019 and has held it in 24 quarters since.
  • Gladstone Institutional Advisory's GSK position peaked at $955K in Q4 2021.
  • 1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.